Abeona Therapeutics Inc. (ABEO)
NASDAQ: ABEO · Real-Time Price · USD
5.54
+0.16 (2.97%)
Apr 22, 2026, 2:58 PM EDT - Market open
Abeona Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Abeona Therapeutics stock have an average target of 20, which predicts a 261.01% increase from the current stock price of 5.54.
Price Target: $20 (+261.01%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 19, 2026.
Analyst Ratings
The average analyst rating for Abeona Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 3 | 3 | 3 | 3 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +261.01% | Mar 19, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +261.01% | Mar 10, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +261.01% | Oct 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +261.01% | Aug 18, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $19 → $20 | Buy | Maintains | $19 → $20 | +261.01% | Aug 15, 2025 |
Financial Forecast
Revenue This Year
65.44M
from 5.82M
Increased by 1,024.31%
Revenue Next Year
160.59M
from 65.44M
Increased by 145.42%
EPS This Year
-0.82
from 1.01
EPS Next Year
0.20
from -0.82
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 103.8M | 197.5M | ||||||
| Avg | 65.4M | 160.6M | ||||||
| Low | 41.5M | 134.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1,683.8% | 201.8% | ||||||
| Avg | 1,024.3% | 145.4% | ||||||
| Low | 612.7% | 105.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.44 | 0.66 | ||||||
| Avg | -0.82 | 0.20 | ||||||
| Low | -1.12 | -0.46 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.